Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance
The share of stand-alone prescription drug plans using coinsurance for preferred brand name drugs surged in recent years, exposing more patients to list prices that are often artificially inflated.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
News
Pharmacies Excluded from Preferred Networks Face Much Higher Risk of Closure
Featured Experts: Dima M. Qato
In The News View All
CalMatters
California’s proposal to establish fiduciary duty for PBMs would be an important cost-saving reform, Joyce says
Featured Experts: Geoffrey Joyce
POLITICO
“Most Favored Nation” could incentivize drugmakers to pull products overseas, hurting patients worldwide, Lakdawalla warns
Featured Experts: Darius Lakdawalla
ABC7
Pharmaceutical tariffs may raise prices and reduce innovation, explains Padula
Featured Experts: William Padula
Modern Healthcare
States are likely to pursue PBM legislation in the absence of federal action, Joyce says
Featured Experts: Geoffrey Joyce
ABC News
Padula says pharmaceutical tariffs could hit R&D budgets
Featured Experts: William Padula
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
